Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.420NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AM.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.237NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
N.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.39.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.29NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.19 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBNNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.233NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.462NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBJ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.635NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.320NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.33NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.356NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.217NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.411NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CA.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.500NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.41NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.75NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.147NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.58NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.487NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-21719.1US
B.1.1.161NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BM.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.35NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.127.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4.2.4 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.68NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.527NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.160.27NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.46NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.121NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
B.1.177.40NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.83NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.115NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AA.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.17 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CA.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AS.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CU.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XFNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used